Key facts
- It has raised $14.3M; the latest was Later Stage VC ($6.6M) in Oct 2025.
- Notable investors include b2venture, NRW.Bank, Fly Ventures, Holland Capital (Private Equity), Bielefeld University — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Semalytix
- ·The full record, as it builds
Funding rounds
No funding rounds for Semalytix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Semalytix
Developer of an AI-based evidence and analytics generation platform designed to capture and generate online patient experiences in multiple therapy areas like oncology, inflammatory diseases, metabolism, and respiratory systems. The company's platform gathers data from patient forums, social media, and other online sources on everyday medication experiences to provide insights, enabling medical and pharmaceutical sector industries make informed decisions that directly impact the success rates of treatment outcomes.
- Sector
- Healthcare
- HQ
- Bielefeld, Germany
- Founded
- 2015
- Employees
- 75
- Website
- semalytix.com/
- Ownership
- Privately Held (backing)
Semalytix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Semalytix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Semalytix in its N-PORT filings yet. We sweep new filings monthly.